Mills RE, Walter K, Stewart C, et al. Mapping copy number variation by population-scale genome sequencing. Nature. 2011;470(7332):59-65. doi:10.1038/nature09708
Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007;39(12):1477-82. doi:10.1038/ng.2007.27
Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77(6):1044-60. doi:10.1086/498651
Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011;70(6):897-912. doi:10.1002/ana.22609
Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases, and what is next?. Curr Opin Immunol. 2012;24(5):571-5. doi:10.1016/j.coi.2012.09.001
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013;31(15):1803-5. doi:10.1200/JCO.2013.49.4799
Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45(12):1483-6. doi:10.1038/ng.2821
Damotte V, Guillot-Noel L, Patsopoulos NA, et al. A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes Immun. 2014;15(2):126-32. doi:10.1038/gene.2013.70
Bergen SE, O’Dushlaine CT, Lee PH, et al. Genetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family history. Schizophr Res. 2014;154(1-3):48-53. doi:10.1016/j.schres.2014.01.030
Robinson EB, Kirby A, Ruparel K, et al. The genetic architecture of pediatric cognitive abilities in the Philadelphia Neurodevelopmental Cohort. Mol Psychiatry. 2015;20(4):454-8. doi:10.1038/mp.2014.65